Hill-Rom Stock Forecast, Price & News

Hill-Rom (NYSE:HRC) Frequently Asked Questions

Is Hill-Rom a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hill-Rom in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Hill-Rom stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HRC, but not buy additional shares or sell existing shares.
View analyst ratings for Hill-Rom or view top-rated stocks.

How has Hill-Rom's stock been impacted by COVID-19 (Coronavirus)?

Hill-Rom's stock was trading at $89.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HRC shares have increased by 74.6% and is now trading at $155.68.
View which stocks have been most impacted by COVID-19.

Are investors shorting Hill-Rom?

Hill-Rom saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 6,570,000 shares, an increase of 23.0% from the October 31st total of 5,340,000 shares. Based on an average daily volume of 1,180,000 shares, the days-to-cover ratio is currently 5.6 days. Approximately 10.0% of the shares of the stock are sold short.
View Hill-Rom's Short Interest.

When is Hill-Rom's next earnings date?

Hill-Rom is scheduled to release its next quarterly earnings announcement on Friday, February 4th 2022.
View our earnings forecast for Hill-Rom.

How were Hill-Rom's earnings last quarter?

Hill-Rom Holdings, Inc. (NYSE:HRC) issued its earnings results on Friday, November, 5th. The medical technology company reported $1.67 EPS for the quarter, beating the Zacks' consensus estimate of $1.47 by $0.20. The medical technology company had revenue of $797.90 million for the quarter, compared to the consensus estimate of $752.97 million. Hill-Rom had a trailing twelve-month return on equity of 23.07% and a net margin of 8.23%. The business's quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.17 EPS.
View Hill-Rom's earnings history.

How often does Hill-Rom pay dividends? What is the dividend yield for Hill-Rom?

Hill-Rom declared a quarterly dividend on Tuesday, November 2nd. Investors of record on Wednesday, December 15th will be paid a dividend of $0.24 per share on Friday, December 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.62%. The ex-dividend date of this dividend is Tuesday, December 14th.
View Hill-Rom's dividend history.

Is Hill-Rom a good dividend stock?

Hill-Rom pays an annual dividend of $0.96 per share and currently has a dividend yield of 0.62%. Hill-Rom has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Hill-Rom is 25.81%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Hill-Rom will have a dividend payout ratio of 13.37% next year. This indicates that Hill-Rom will be able to sustain or increase its dividend.
View Hill-Rom's dividend history.

What price target have analysts set for HRC?

6 Wall Street analysts have issued 1 year target prices for Hill-Rom's shares. Their forecasts range from $122.00 to $156.00. On average, they anticipate Hill-Rom's stock price to reach $144.00 in the next year. This suggests that the stock has a possible downside of 7.5%.
View analysts' price targets for Hill-Rom or view top-rated stocks among Wall Street analysts.

Who are Hill-Rom's key executives?

Hill-Rom's management team includes the following people:

• John P. Groetelaars, President, Chief Executive Officer & Director
• Tim Lawrence, Senior Vice President-Operations
• Barbara W. Bodem, Chief Financial Officer & Senior Vice President
• Brian L. Lawrence, Chief Technology Officer & SVP-Innovation
• Ilana Shulman, Chief Compliance Officer

What is John P. Groetelaars' approval rating as Hill-Rom's CEO?

54 employees have rated Hill-Rom CEO John P. Groetelaars on Glassdoor.com. John P. Groetelaars has an approval rating of 82% among Hill-Rom's employees.

Who are some of Hill-Rom's key competitors?

Some companies that are related to Hill-Rom include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), DexCom (DXCM), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Masimo (MASI).
View all of HRC's competitors.

What other stocks do shareholders of Hill-Rom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hill-Rom investors own include Steel Dynamics (STLD), Walt Disney (DIS), NVIDIA (NVDA), Square (SQ), PayPal (PYPL), salesforce.com (CRM), CVS Health (CVS), Micron Technology (MU), AbbVie (ABBV) and Bank of America (BAC).

What is Hill-Rom's stock symbol?

Hill-Rom trades on the New York Stock Exchange (NYSE) under the ticker symbol "HRC."

Who are Hill-Rom's major shareholders?

Hill-Rom's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.98%), Victory Capital Management Inc. (3.78%), Wellington Management Group LLP (3.34%), Alpine Associates Management Inc. (1.85%), Magnetar Financial LLC (1.54%) and Geode Capital Management LLC (1.26%). Company insiders that own Hill-Rom stock include Amy M Dodrill, Andreas G Frank, Deborah Rasin, Jeffrey F Dimodica, Mary Kay Ladone and Paul Sherwood Johnson.
View institutional ownership trends for Hill-Rom.

Which institutional investors are selling Hill-Rom stock?

HRC stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Victory Capital Management Inc., Fisher Asset Management LLC, Invesco Ltd., LSV Asset Management, BlackRock Inc., Neuberger Berman Group LLC, and Boston Trust Walden Corp. Company insiders that have sold Hill-Rom company stock in the last year include Deborah Rasin, Jeffrey F Dimodica, Mary Kay Ladone, and Paul Sherwood Johnson.
View insider buying and selling activity for Hill-Rom or view top insider-selling stocks.

Which institutional investors are buying Hill-Rom stock?

HRC stock was acquired by a variety of institutional investors in the last quarter, including Alpine Associates Management Inc., Magnetar Financial LLC, Citigroup Inc., Capitolis Advisors LLC, Deutsche Bank AG, Versor Investments LP, Westchester Capital Management LLC, and Soros Fund Management LLC.
View insider buying and selling activity for Hill-Rom or or view top insider-buying stocks.

How do I buy shares of Hill-Rom?

Shares of HRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hill-Rom's stock price today?

One share of HRC stock can currently be purchased for approximately $155.68.

How much money does Hill-Rom make?

Hill-Rom has a market capitalization of $10.28 billion and generates $3.02 billion in revenue each year. The medical technology company earns $248.50 million in net income (profit) each year or $3.72 on an earnings per share basis.

How many employees does Hill-Rom have?

Hill-Rom employs 10,000 workers across the globe.

What is Hill-Rom's official website?

The official website for Hill-Rom is www.hill-rom.com.

Where are Hill-Rom's headquarters?

Hill-Rom is headquartered at 130 East Randolph Street Suite 1000, Chicago IL, 60601.

How can I contact Hill-Rom?

Hill-Rom's mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company can be reached via phone at (312) 819-7200, via email at [email protected], or via fax at 812-934-8189.